Literature DB >> 30351207

Report of Confirmation of the rs7853758 and rs885004 Haplotype in SLC28A3.

Wesley M Stansberry1, Marelize Swart2, Elizabeth B Medeiros1, Todd C Skaar2, Victoria M Pratt1.   

Abstract

AIMS: To validate a laboratory-developed test for the nucleoside transporter, SLC28A3, which has been associated with an increased risk of anthracycline-induced cardiomyopathy.
METHODS: We used Taqman® allele discrimination to test for two variants of the SLC28A3 gene: rs7853758 (c.1381C>T) and rs885004 (c.862-360C>T).
RESULTS: During the validation process, we noted that several DNA samples obtained from the Coriell Cell Repository (Camden, NJ) were positive for both the c.1381 C > T and c.862-360C>T variants and another variant allele for either c.1381 C > T or c.862-360C>T (e.g., c.1381C>T homozygous/c.862-360C>T heterozygous, c.1381C>T homozygous/c.862-360C>T homozygous). We used de-identified DNA samples from trios of family members (mother, father, and child) to establish that the c.1381 C > T and c.862-360C>T variant alleles could be inherited in cis on the same chromosome.
CONCLUSIONS: Samples containing three variant alleles suggest that the c.1381 C > T and c.862-360C>T are in cis on the chromosome in some individuals and may have implications when calculating anthracycline-induced cardiomyopathy risk. In this study, we confirm a novel haplotype of SLC28A3 using familial studies.

Entities:  

Keywords:  SLC28A3; haplotype; pharmacogenetics; rs7853758; rs885004

Mesh:

Substances:

Year:  2018        PMID: 30351207      PMCID: PMC6249667          DOI: 10.1089/gtmb.2018.0194

Source DB:  PubMed          Journal:  Genet Test Mol Biomarkers        ISSN: 1945-0257


  10 in total

1.  Primer3 on the WWW for general users and for biologist programmers.

Authors:  S Rozen; H Skaletsky
Journal:  Methods Mol Biol       Date:  2000

2.  Readmissions and adverse drug reactions in internal medicine: the economic impact.

Authors:  H Dormann; A Neubert; M Criegee-Rieck; T Egger; M Radespiel-Tröger; T Azaz-Livshits; M Levy; K Brune; E G Hahn
Journal:  J Intern Med       Date:  2004-06       Impact factor: 8.989

3.  Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies.

Authors:  J Lazarou; B H Pomeranz; P N Corey
Journal:  JAMA       Date:  1998-04-15       Impact factor: 56.272

Review 4.  Sequencing the CYP2D6 gene: from variant allele discovery to clinical pharmacogenetic testing.

Authors:  Yao Yang; Mariana R Botton; Erick R Scott; Stuart A Scott
Journal:  Pharmacogenomics       Date:  2017-05-04       Impact factor: 2.533

5.  Detection of 677CT/1298AC "double variant" chromosomes: implications for interpretation of MTHFR genotyping results.

Authors:  Nicholas M Brown; Victoria M Pratt; Arlene Buller; Lisa Pike-Buchanan; Joy B Redman; Weimin Sun; Rebecca Chen; Beryl Crossley; Matthew J McGinniss; Franklin Quan; Charles M Strom
Journal:  Genet Med       Date:  2005-04       Impact factor: 8.822

6.  Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children.

Authors:  Henk Visscher; Colin J D Ross; S Rod Rassekh; Amina Barhdadi; Marie-Pierre Dubé; Hesham Al-Saloos; George S Sandor; Huib N Caron; Elvira C van Dalen; Leontien C Kremer; Helena J van der Pal; Andrew M K Brown; Paul C Rogers; Michael S Phillips; Michael J Rieder; Bruce C Carleton; Michael R Hayden
Journal:  J Clin Oncol       Date:  2011-09-06       Impact factor: 44.544

Review 7.  Contribution of specific transport systems to anthracycline transport in tumor and normal cells.

Authors:  K Nagasawa; K Nagai; N Ohnishi; T Yokoyama; S Fujimoto
Journal:  Curr Drug Metab       Date:  2001-12       Impact factor: 3.731

8.  Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children.

Authors:  H Visscher; C J D Ross; S R Rassekh; G S S Sandor; H N Caron; E C van Dalen; L C Kremer; H J van der Pal; P C Rogers; M J Rieder; B C Carleton; M R Hayden
Journal:  Pediatr Blood Cancer       Date:  2013-02-25       Impact factor: 3.167

9.  PharmGED: Pharmacogenetic Effect Database.

Authors:  C J Zheng; L Y Han; B Xie; C Y Liew; S Ong; J Cui; H L Zhang; Z Q Tang; S H Gan; L Jiang; Y Z Chen
Journal:  Nucleic Acids Res       Date:  2006-12-06       Impact factor: 16.971

10.  Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel.

Authors:  Michael S Watson; Garry R Cutting; Robert J Desnick; Deborah A Driscoll; Katherine Klinger; Michael Mennuti; Glenn E Palomaki; Bradley W Popovich; Victoria M Pratt; Elizabeth M Rohlfs; Charles M Strom; C Sue Richards; David R Witt; Wayne W Grody
Journal:  Genet Med       Date:  2004 Sep-Oct       Impact factor: 8.822

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.